This study evaluated whether the neutrophil-to-lymphocyte ratio (NLR) can predict disease recurrence after treatment with prostate surgery. Researchers reported a strong association between high NLR and disease recurrence after prostate surgery.

The authors aimed to determine the effect of tumor-directed stereotactic body radiotherapy in prostate cancer patients with oligometastases.

The authors concluded that tumor-directed stereotactic body radiotherapy was a useful treatment for both oligorecurrent and oligoprogressive castration-resistant prostate cancer. 

This study examined the effect of specialized radiation treatments on patient-reported rectal bleeding. The authors found very low rates of rectal bleeding immediately after treatment and at 2 years.

This study compared surgery and radiotherapy for treating localized prostate cancer. They found no significant difference in survival between the two treatments.

The authors aimed to determine whether moderate hypofractionated radiotherapy would worsen sexual function after treatment.

This study examined the effect of cholesterol-lowering drugs (statins) on treatment outcomes following prostate surgery. Researchers found no link between statin use and disease recurrence risk after treatment with prostate surgery.

This study compared the safety and effectiveness of external beam radiation therapy (EBRT) and hypofractioned EBRT (H-EBRT) for localized prostate cancer. Researchers reported no differences in survival or disease recurrence rates between high H-EBRT and EBRT.

This study attempted to examine the contribution of different components of prostate cancer on the outlook of patients diagnosed with metastatic disease despite treatment.